Ranbaxy Laboratories Limited

By: Pharma Tips | Views: 11678 | Date: 16-May-2012

Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 43 countries, world-class manufacturing facilities in 8 countries and serves customers in over 125 cou



Ranbaxy Laboratories Limited

Ranbaxy Laboratories Limited

Company Profile

Ranbaxy Laboratories Limited (Ranbaxy), India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy today has a presence in 23 of the top 25 pharmaceutical markets of the world. The Company has a global footprint in 43 countries, world-class manufacturing facilities in 8 countries and serves customers in over 125 countries.

In June 2008, Ranbaxy entered into an alliance with one of the largest Japanese innovator companies, Daiichi Sankyo Company Ltd., to create an innovator and generic pharmaceutical powerhouse. The combined entity now ranks among the top 20 pharmaceutical companies, globally. The transformational deal will place Ranbaxy in a higher growth trajectory and it will emerge stronger in terms of its global reach and in its capabilities in drug development and manufacturing.

Ranbaxy was incorporated in 1961 and went public in 1973.

 

Mission

Ranbaxy's mission is 'Enriching lives globally, with quality and affordable pharmaceuticals'.

Financials


For the year 2011, the Company recorded Global Sales of US $ 2.1 Bn. The Company has a balanced mix of revenues from emerging and developed markets that contribute 47% and 46% respectively. In 2011, North America, the Company's largest market contributed sales of US $ 791 Mn, Europe contributing US $ 297 Mn and Asia clocking sales of US $ 503 Mn.

Strategy


Ranbaxy is focused on increasing the momentum in the generics business in its key markets through organic and inorganic growth routes. Growth is well spread across geographies with focus on developed and emerging markets. It is the Company's constant endeavour to provide a wide basket of generic and innovator products, leveraging the unique Hybrid Business Model with Daiichi Sankyo. The Company will also increasingly focus in high growth potential segments like Vaccines and Biogenerics. These new areas will add significant depth to the existing product pipeline.

R&D

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide a sustainable, long-term competitive advantage. The Company has a pool of over 1,200 R&D personnel engaged in path-breaking research.

Ranbaxy is among the few Indian pharmaceutical companies in India to have started its research program in the late 70's, in support of its global ambitions. A first-of-its-kind world class R&D centre was commissioned in 1994. Today, the Company has multi-disciplinary R&D centers at Gurgaon, in India, with dedicated facilities for generics research and innovative research. The R&D environment reflects its commitment to be a leader in the generics space offering value added formulations and development of NDA/ANDAs, based on its Novel Drug Delivery System (NDDS) research capability. Ranbaxy's first significant international success using the NDDS technology platform came in September 1999, when the Company out-licensed its first once-a-day formulation to a multinational company.

In July 2010, Ranbaxy's New Drug Discovery Research (NDDR) was transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global Research and Development structure of the Daiichi Sankyo Group. NDDR is now an integral part of Daiichi Sankyo Life Science Research Center in India, based in Gurgaon.

However, Ranbaxy continued to independently develop the anti-malarial new drug, arterolane maleate + piperaquine phosphate that has been approved by the Indian Drug Regulator, Drug Controller General of India (DCGI) for manufacturing and marketing in India. In April 2012, Ranbaxy launched India's first new drug, SynriamTM, for the treatment of uncomplicated Plasmodium falciparum malaria, in adults.

The company will also explore the further development of late stage programs developed by NDDR in the last few years, including the development programs in the GSK collaboration. Within Ranbaxy, R&D of Generics will now get a sharper focus, as the Company is increasingly working on more complex and specialist areas.

People


The Company's business philosophy based on delivering value to its stakeholders constantly inspires its people to innovate, achieve excellence and set new global benchmarks. Driven by the passion of it's over 14,000 strong multicultural workforce comprising of more than 50 nationalities, Ranbaxy continues to aggressively pursue its mission of 'Enriching lives globally, with quality and affordable pharmaceuticals'.

History

When we set out on our way in 1961, little did we realise the impact we would make on the Indian and global pharmaceutical industry.

Worldwide Operations

Global Pharma Companies are experiencing an ever changing landscape ripe with challenges and opportunities. In this challenging environment Ranbaxy is enhancing its reach leveraging its competitive advantages to become a top global player.

Driven by innovation and speed to market we focus on delivering world-class generics at an affordable price. Our unwavering determination to achieve excellence leads us to new global benchmarks. Our people have consistently risen above all challenges maximized opportunities and positioned Ranbaxy as a leader in the global generics space.

Ranbaxy’s global footprint extends to 46 countries embracing different locales and cultures to form a family of 50 nationalities with an intellectual pool of some of the best minds in the world.

Manufacturing Facilities

An organisations' capabilities and intent are strongly reflected in the product it manufactures. In other words, the manufacturing competencies and facilities echo truly, the R&D extent and the ability to implement it for the best of the market it targets.

RANBAXY® possesses the manufacturing strengths that have established it as a producer of world-class generics, branded generics and a major supplier of its range of Active Pharmaceutical Ingredients for pharmaceutical products of companies worldwide.

Ranbaxy has world-class manufacturing facilities in 8 countries namely Ireland, India, Malaysia, Morocco, Nigeria, Romania, South Africa, and USA. Its overseas facilities are designed to cater to the requirements of the local regulatory bodies of that country while the Indian facilities meet the requirements of all International Regulatory Agencies. Some of the agencies such as MCA-UK, MCC-South Africa, FDA-USA and TGA-Australia, have audited Ranbaxy’s manufacturing facilities for the compliance with international Good Manufacturing Practices and have registered its products for safety, quality and efficacy.

Products

Using the finest R&D and Manufacturing facilities, Ranbaxy Laboratories Limited manufacture and markets generic pharmaceuticals, value added generic pharmaceuticals, branded generics, active Pharmaceuticals (API) and intermediates.

The Company remains focused on ascending the value chain in the marketing of pharmaceutical substances and is determined to bring in increased revenues from dosage forms sales.

Ranbaxy's diverse product basket of over 5,000 SKUs available in over 125 countries worldwide, encompasses a wide therapeutic mix covering a majority of the chronic and acute segments. Healthcare trends project that the chronic treatment segments will outpace the acute treatment segments, primarily driven by a growing aging population and dominance of lifestyle diseases. Our robust performance in Cardiovasculars, Central Nervous System, Respiratory, Dermatology, Orthopedics, Nutritionals and Urology segments, clearly indicates that the Company has strengthened its presence in the fast-growing chronic and lifestyle disease segments.

Top 10 Molecules (2010)
• Valacyclovir
• Simvastatin
• Donepezil
• Atorvastatin & Combinations
• Co-amoxyclav & Combinations
• Ciprofloxacin & Combinations
• Ketorolac Tromethamine
• Imipenem+Cilastatin
• Ginseng+Vitamins
• Loratadine & Combinations

Human Resource

A career at Ranbaxy means an opportunity for ample learning & growth. It offers avenues to work across the globe along side the finest minds. The Company offers a challenging assignment, a world class working environment, professional management, competitive salaries, stock options along with exceptional rewards.

If you have an appetite for challenges, we have an exciting career for you

Opportunities

The global spread of Ranbaxy and the blazing growth in business provides ample opportunities for our employees to build careers in various fields. Opportunities have never been a constraint for the deserving. We believe in employee growth that goes beyond vertical movements and change in designations. Potential and performance are the pillars of career progression at Ranbaxy. A robust development process supports this.

Our managers will generally have the opportunity to live and work in different countries; such international experience will help them better understand our complex business and grow both personally and professionally.

Salary and Benefits

Salaries and other benefits in Ranbaxy are comparable with the best in the industry and one can expect to be rewarded highly if the performance is consistently outstanding.

Group Life Insurance, Medical Insurance and Pension plans are a few examples of the benefits we provide to our employees and their dependents with adequate financial protection on long term basis.

Stock Ownership

The ownership in business is fundamental to personal progression, we encourage you to take ownership of your investments.

Stock ownership is a part of the compensation for our managers early in their career at Ranbaxy: you will see the business results straight in your pay slip!

Work Environment

Autonomy and entrepreneurship: We believe in providing autonomy to our employees and let them discover their potential while working for Ranbaxy. Individuals are given responsibility quite early in their careers and their actions impact the business. This has helped in fostering a culture of entrepreneurship within the organisation that we are extremely proud of.

Creativity and Innovation: Supporting this entrepreneurial culture is the spirit of innovation and creativity. You do not need to be part of Research and Development to bring about innovations. Creativity is promoted in every part of the organisation. Genuine mistakes are considered as part of learning and calculated risk taking is encouraged.

Diversity: Ranbaxy is an equal opportunity employer and that gets reflected in the rich and diverse workforce. This diversity provides us the strength to reach out to the world and touch the lives of millions of people in different parts of the globe. We value the diversity that exists within our employees and leverage this to bring about synergy within the organisation. Ranbaxy workforce of around 14000 people is represented by 51 nationalities with approximately 26% constituting foreign nationals.

Employee Development

Employees represent what a company stands for. The value an organisation produces is unequivocally linked to collective efforts of its people. We at Ranbaxy realize that the growth of the company can be sustained through the continuous development of people who contribute to the business success. Hence we focus our attention to harness the innate potential each individual brings to the organisation.

Identifying Potential

While the initial years in the career of a Ranbaxy manager is used in developing the professional skills, the focus changes as a person moves to the middle management level. Here leadership potential becomes critical. We have a robust process of identifying potential in individuals. Each of our middle level managers goes through a process that clearly identifies their strengths, development areas and aspirations for the future. This is supported by a structured process of development, which includes movement within the organisation.

Building Leaders Across the Organisation

We believe that every individual can be a leader and leadership is not a domain of the people at the top. Accordingly the Ranbaxy Leadership Model focuses on strengthening the leadership qualities across the organisation and quite early in the individual's career. The Model prepares individuals first to deal with 'the self' and then with 'others'. As the manager matures, the model facilitates the individual to become a business leader by understanding and appreciating the multiple facets of business. Finally managers of Ranbaxy are prepared to lead and drive change - an ultimate test of a person's leadership skills

In addition, as an employee of Ranbaxy, you can expect to be trained in the latest developments in your respective field of functional excellence. Our Strategic Learning Partners support the development initiatives at Ranbaxy and are themselves leading names / institutions in the world of people development

The Management Trainee Programme

In order to bring consistent growth, sustainability and novelty to our business operations  we at Ranbaxy follow a special “Management Trainee Programme”.   

This programme aims at developing and nurturing young talents identified from premier Management Institutes of the country and trains them to excel in their respective area of specialization through on-job-trainings. Both behavioral and Functional trainings are imparted to them.  They are put into diverse fields of businesses and challenging assignments which enables them to be fully prepared to tackle any business challenges of tomorrow thereby moulding them to be our future leaders.    Care has also been taken to provide them with ample opportunities for their personal and professional development.

Management Trainees are provided with live projects which expose them to the various facets of business realities.   They are not only under rotation in different fields of activities during their tenure but also work in Cross Functional Teams exposing them to deal with inter-related, complex and critical activities of business.   Specific project assignments are also given under supervision and guidance of senior management members and periodic progress is monitored.   They are also given inter-location trainings to get them familiarized with in-depth understanding of the functions at various stages of the business activity.  

Throughout the process, hand-holding and guidance of Global OD Function ensures all management Trainees make most out of their unique learning experience.  After successful completion, a special evaluation committee constituted conducts merit driven evaluation of their results and performance under different projects.  Based on their overall performance of the entire training period, they are regularized as  Managers and accommodated into various departments of the organization.  This unfolds the second phase of their journey of learning and achievements.

Research & Development

 
 

Ranbaxy views its R&D capabilities as a vital component of its business strategy that will provide a sustainable, long-term competitive advantage. The company has a pool of over 1,200 R&D personnel engaged in path-breaking research.

Ranbaxy is among the few Indian pharmaceutical companies in India to have started its research program in the late 70's, in support of its global ambitions. A first-of-its-kind world class R&D centre was commissioned in 1994. Today, the company has multi-disciplinary R&D centers at Gurgaon, in India, with dedicated facilities for generics research and innovative research. The R&D environment reflects its commitment to be a leader in the generics space offering value added formulations and development of NDA/ANDAs, based on its Novel Drug Delivery System (NDDS) research capability.

The NDDS research at Ranbaxy focuses on maximizing the overall therapeutic and commercial value of commonly prescribed pharmaceutical formulations by enhancing their performance and reducing their adverse event profile. Such innovation also helps to improve the overall patient convenience and compliance

The company's NDDS focus is mainly on the development of New Drug Applications (NDA) / Abbreviated New Drug Applications (ANDAs) of oral controlled- release products for the regulated markets. The Company's first significant international success using the NDDS technology platform came in September 1999, when Ranbaxy licensed its once-a-day Ciprofloxacin formulation on a worldwide basis to a multinational Company.

Ranbaxy's in-house NDDS programs are primarily focused on the oral segment. Inhalation (patented devices) and trans-dermal (patented adhesive polymers) programs are also being pursued through collaborations.

In the oral NDDS space, Ranbaxy has already developed four platform technologies namely Gastro Retentive, Modified Matrix, Multiparticulate and AeroGel. Several products leveraging these technologies have been successfully developed.

In July 2010, Ranbaxy’s New Drug Discovery Research (NDDR) was transferred to Daiichi Sankyo India Pharma Private Limited as part of the strategy to strengthen the global Research and Development structure of the Daiichi Sankyo Group. While NDDR has become an integral part of Daiichi Sankyo Life Science Research Center in India, based in Gurgaon, Ranbaxy continued to independently develop the anti-malarial new drug, Arterolanemaleate + Piperaquine phosphate. In 2011, Ranbaxy received permission from the Indian Drug Regulator, Drug Controller General of India (DCGI), to manufacture and market this drug in India. The company has now launched India’s first new drug, SynriamTM, for the treatment of uncomplicated Plasmodium falciparum malaria, in adults.

Ranbaxy will also explore the further development of late stage programs developed by NDDR in the last few years, including the development programs in the GSK collaboration.

Within Ranbaxy, R&D of Generics will now get a sharper focus, as the company is increasingly working on more complex and specialist areas.

Global API
Profile

Active Pharmaceutical Ingredients (API)


Ranbaxy's API business has grown consistently over the years. In a macro environment of extra ordinary competition and challenges, the API division has moved from strength to strength.

TRULY GLOBAL API DIVISION

Supplies top-of-the-line APIs to leading innovator and generic companies in more than 65 countries.

TOTAL SOLUTIONS

*CSMS – Custom Synthesis & Manufacturing Services
  • Actives: Over 40 years of expertise in making APIs, makes us the partner of choice for both Innovators and Generics.
  • Intermediates: Advanced intermediates of most of the products are provided.
  • Custom Synthesis and Manufacturing Services (CSMS): We provide Custom synthesis services utilizing our rich experience in novel ways of synthesizing and Contact Manufacturing services backed by kilo lab in R&D, pilot plants and cGMP manufacturing sites.

FOCUS GEOGRAPHIES

North America, Europe, Latin America, Middle East, China, Far East and Select Asian Markets.

WIDE THERAPEUTIC COVERAGE

Cardio-Vascular,  Anti-Infectives,  Anti-ulcerants,  Anti-diabetics,  Anti-depressants,  Anti-virals  and others.


Research & Development

Ranbaxy views its API R&D capabilities as a vital component of its business strategy that will provide a sustainable, long-term competitive advantage.

  • Dedicated Facilities for Innovative & Generics API Research.
  • More than 250 Personnel (about 60 Doctorates).
  • One of the highest R&D spenders among Indian pharmaceutical companies.
  • R & D Collaborations with global research companies.

Product Development program

  • Development, scale-up and commercialization of cost-efficient, innovative processes.
  • Selection of appropriate salts and polymorphs for APIs.
  • Development of innovative chemistry for Custom Synthesis involving kilo scale to commercial quantities.
  • Synthesis and characterization of impurities and degradation products of APIs.
  • IP creation in the API organization – Total No. of patents filed : ~800

Regulatory

Ranbaxy has rich experience in timely filings of regulatory dossiers in various leading regulatory authorities in conformance with current regulatory requirements.  Our Qualified team is prompt in handling  regulatory queries from  authorities & customers effectively and  efficiently.


Intellectual Property (IP)

Ranbaxy has a qualified team of about 50 IP professionals including In house counsels continuously working on creating and protecting value to customer

  • Due Diligence   
  • Patent portfolio management                   
  • Identifying opportunities proactively
  • Long patent litigation experience
  • Efficient Product and process clearance

Manufacturing

Ranbaxy has four manufacturing facilities for API across India, encompassing manufacturing of Active Pharmaceutical Ingredients and Intermediates.

Our manufacturing facilities have been inspected and approved by the leading regulatory authorities.

Toansa,
Punjab
  • Producing over 100 API’s
  • Accreditations from: USFDA, EDQM, EUGMP, PMDA, TGA, MCC

Dewas,
Madhya Pradesh

  • Non beta lactums, Macrolides & Carbapenems
  • Accreditations from: EDQM, EUGMP, PMDA, TGA, MCC

Paonta Sahib,
Himanchal Pradesh

  • Fermentation facility
  • Accreditations from: EDQM, EUGMP, PMDA, TGA, MCC

Malanpur,
Madhya Pradesh

  • Intermediate facility




 


 
Mr. Govind K Jaju
Senior Vice President - Global Material Sourcing and API Business
Ranbaxy Laboratories Limited
Plot No. 90, Sector 32
Gurgaon - 122 001, India
Email: api@ranbaxy.com
 

An introduction to RGCH

 
Moving up the value chain, Ranbaxy identified Consumer Healthcare as its new business area in the year 2001. Subsequently, Ranbaxy Global Consumer Healthcare (RGCH) business was initiated with the launch of 4 brands: Revital, Pepfiz, Gesdyp & Garlic Pearls.
 
 
These brands had a strong equity with consumers and represented the leading common ailment categories like VMS (Vitamins & Minerals Supplement), this portfolio was carefully crafted for the introduction of Ranbaxy's consumer healthcare business in India.
 
 
Subsequently in 2004, RGCH launched its first herbal range of products through New Age Herbals (NAH), with products offering remedies in categories of Cough & Cold (Olesan Oil & Cough Syrups) and Appetite Stimulant (Eat Ease).
 
 
In 2005, another popular brand, Chericof – The complete cough formula was introduced.
 
 
During 2009, the business registered sales of US $ 44 Mn registering a growth of 12%.
 
 
Revital, the flagship brand continues to maintain leadership in its segment.
 

The Rainbow Coalition

 
RGCH has chosen a unique Business Communication platform 'The Rainbow Coalition' which is an integrated communication program targeted at doctors at one end and consumers at the other.
 
 
In line with this approach, the business continues to reach out to the Doctors to generate prescriptions flow and enhance doctor endorsements for RGCH brands.Simultaneously consumer communication and widespread availability of the product has helped in enhanced coverage
 
 
This Rainbow Coalition effort has resulted in sales and prescription growth
 

Sales and Distribution


RGCH pursued a differentiated sales & distribution Strategy of engaging, FMCG distributors for its products, a first of its kind attempt at Ranbaxy.


The distribution infrastructure of RGCH continues to grow with about 600 Distributors and Distributor Sales Representatives (DSRs) representing RGCH in the Indian market.

The Road ahead – future plans


Organic and inorganic growth is planned through strategic alliances and/or acquisitions in the large and exciting OTC and Herbal markets. These expansions will serve the consumer and enhance value for its stakeholders


In its first phase of geographical expansion, RGCH continues to focus on ‘growth countries’ which include Russia, Ukraine, Romania, Vietnam, Myanmar and Malaysia. The next stage of expansion is planned in Central and East European countries

RGCH Product List


S No
Brand name
Generic name
Therapeutic segment
 
1
CHERICOF COUGH SYRUP
Complete Cough Syrup for family
CCA - Cough, Cold & Allergy
 
2
CHERICOF SOFTGEL
Cough remedy capsules
CCA - Cough, Cold & Allergy
 
3
EATEASE
Appetite enhancer-Children (Herbal)
GI - Gastro-intestinals
 
4
GARLIC PEARLS
Garlic oil for all round health
GI - Gastro-intestinals
 
5
GESDYP
Digestive Enzymes
GI - Gastro-intestinals
 
6
OLESAN GEL
Cold rub (Herbal)
CCA - Cough, Cold & Allergy
 
7
OLESAN LOZENGES
Cough & sore throat cure ( Herbal)
CCA - Cough, Cold & Allergy
 
8
OLESAN OIL
Nasal decongestant oil (Herbal)
CCA - Cough, Cold & Allergy
 
9
PEPFIZ
Effervescent digestive enzymes
GI - Gastro-intestinals
 
10
REVITAL SOFTGELS
Ginseng, vitamins & minerals
VMS-Vitamins, Minerals & Supplements
 
11
REVITAL LIQUID
Ginseng, vitamins & minerals
VMS-Vitamins, Minerals & Supplements
  12 REVITAL SENIOR Vitamins, Minerals, Ginseng and Isoflavones
(Specially formulated for 50 years+)
VMS – Vitamins, Minerals and Supplements
  13 REVITAL WOMAN Ginseng, Vitamins and Minerals
(Specially formulated for women)
VMS – Vitamins, Minerals and Supplements
 
14
REVITALITE

Soy Protein Supplement

VMS – Vitamins, Minerals & Supplements

 
15
VOLINI GEL
Complete Pain relief Gel
ANALGESIC-Topical
 
16
VOLINI SPRAY
Complete Pain relief Spray
ANALGESIC-Topical
  17 VOLINI TABS Complete Pain relief tabs ANALGESIC-Oral

Contact:
Vice President – Ranbaxy Global Consumer Healthcare
Corporate Office, Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: +91-124-4135000
Email: brijesh.kapil@ranbaxy.com

Business Development & Partnerships

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, headquartered in India, is an integrated, research based, international pharmaceutical company, producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company has a ground presence in 43 countries, manufacturing operations in 8 countries and sells products in over 125 countries.

The Company has adopted a multi-pronged strategy. Acquisition of generic brands overseas, strong emphasis on brand marketing in the US and Europe, entering high potential new markets with value added product offerings, are the major thrust areas. Successful business development transactions form a key component of its business strategy.

In each of our partnerships, we strive to build enduring, mutually beneficial relationships that can produce positive results for both parties.

We are interested in sales and marketing partnerships and product acquisition opportunities in all the markets where we operate. We are exploring opportunities through Licensing and Alliances to draw maximum value from such arrangements. We continue to evaluate opportunities to add to our product basket, enhance our therapeutic presence and expand our distribution reach.

For business development, licensing, and partnership enquiries please contact:

Toshiyuki Sato
Head - Global Corporate Development

Ranbaxy Laboratories Limited
Plot No. 90, Sector 32,
Gurgaon – 122001 (Haryana), India
E-mail: Business.Development@ranbaxy.com



Contact Us

Thank you for visiting Ranbaxy online.
CORPORATE OFFICE GURGAON
CORPORATE OFFICE GURGAON


Ranbaxy Laboratories Limited

Corporate Office
Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: 91- 124- 4135000
Fax: 91-124-4135001


Registered Office
A-41, Industrial Area Phase VIII-A,
Sahibzada Ajit Singh Nagar,
Mohali - 160 071 (Punjab), INDIA


Other Contacts


 MEDIA QUERIES

Mr. Krishnan Ramalingam
General Manager, Corporate Communications
Ph: +91-124-4135143, 4135000
Email: krishnan.ramalingam@ranbaxy.com


Mr. Gaurav Chugh
Sr. Manager, Corporate Communications
Ph: +91-124-4135145, 4135000
Email: gaurav.chugh@ranbaxy.com


 INVESTOR RELATIONS

Registration of Complaints by Investors

Mr. S. K. Patawari
Company Secretary
Ranbaxy Laboratories Ltd.
Plot No. 90, Sector 32
Gurgaon - 122001 (Haryana), India
Ph: +91-124-4135000
Fax: +91-124-4106490
Email: secretarial@ranbaxy.com



Secretarial Services

Mr. Navneet Raghuvanshi
Deputy Company Secretary
Email: navneet.raghuvanshi@ranbaxy.com



 RESEARCH & DEVELOPMENT CENTER

Plot No. 20, Sector - 18,
Udyog Vihar Industrial Area
Gurgaon, Haryana-122001, INDIA
Ph: 91- 124 2342001-10
Email: udbhav.ganjoo@ranbaxy.com


 GLOBAL API

Mr. Govind K Jaju
Senior Vice President - Global Material Sourcing and API Business
Ranbaxy Laboratories Limited
Plot No. 90, Sector 32
Gurgaon - 122 001, India
Email: api@ranbaxy.com


 GLOBAL CONSUMER HEALTHCARE

Mr. Brijesh Kapil
Vice President – Ranbaxy Global Consumer Healthcare
Corporate Office, Plot 90, Sector 32,
Gurgaon -122001 (Haryana), INDIA
Ph: +91-124-4135000
Email: brijesh.kapil@ranbaxy.com


 RANBAXY COMMUNITY HEALTHCARE SOCIETY

Dr. R.S.Bakshi
Chief Medical Officer-RCHS
Corporate Office, Plot 90, Sector 32,
Gurgaon -122001 ( Haryana), INDIA
Ph: +91- 124- 4135000
Email: ranbir.bakshi@ranbaxy.com


 RANBAXY SCIENCE FOUNDATION

Mr. Dr. Rajinder K Jalali
Vice President
Ranbaxy Research Laboratories Limited,
Plot No. 77B, Sector - 18, IFFCO Road,
Gurgaon -122001 (Haryana), INDIA
Ph: +91-124-5194207
Email: rajinder.jalali@ranbaxy.com

Ranbaxy Laboratories Ltd.
32 Plot 90, Sector,
GURGAON 122 001 India
Tel: 0124-4135000
Fax: 0124-4135001
Website: www.ranbaxy.com 
 


Products of Ranbaxy

•ACCUSPOT HIV-1/2 •LUCI-N
•ACMIL •LULIFIN
•ACROTAC •MACROGEN
•ADHEB •MEDAPINE
•AEROMIST •MELUBRIN
•ALFAKIM •MINOZ
•AMEXIDIL-5 •MOBISWIFT-D
•APRELIEF •MOBRINE-IR
•ARTAGEN •NEURONOX
•ASPENT •NIAVAS
•AVESSA •NIFTRAN
•CALIBS •NOCULI TAB
•CALSLOT •NORAZOL
•CALURAN •OSONASE
•CALURAN-CP •PIMERA
•CANDESAR-H •PRASITA
•CAPSOLA •PRECIZE
•CAPSOLA PLUS •RACIPER SF
•CARDIBETA-AM •RACIPER-D
•CARDIBETA-XR •RACIPER-IV 40
•CAREVON •RANBIOTIC
•CASERA •RANODINE
•CASPORAN •REFPIM FORTE
•CEFDIEL •REFPIM
•CEFDITRAN •REFZIL-O
•CEFTOP INJ •REMICRON MR
•CELIPRES •REVULANT
•CEROXIM-XP •RHEOLIN
•CERUVIN-A •RHEORAN-SF 125
•CERUVIN-AF •RHEORAN-SF 250
•CHLORAMSONE •RHEORAN-SF 50
•CIFRAN-CT-H •RHEORAN-SF RHEOCAPS
•CIFRAN-OZ •RICONIA SILVER
•CILANEM •RICONIA SYR
•CIPROACE •RICONIA TAB
•CLEANODERM •RICONIA-G
•COHERO •RICONIA-LP
•CONADERM •RIOMET-DUO
•CONDERM •RIOMET-G
•CONTIFLO ICON •RIOMET-TRIO
•CONTIFLO-D •ROBUROL
•CONTIFLO-OD •ROFIBAX
•CORPRIL •ROLES-D
•COTUSS •ROLES-SF
•COVANCE •ROLIFLO-OD
•COVANCE-D •ROLITEN
•COVANCE-D CP •ROLITEN-OD
•CROLIM OINT •ROMILAST GRANULES
•CROLIM POWER •ROMILAST-B5
•DARITEN-OD •ROMILAST-L
•DARVOCET •ROSCILLIN
•DECROMA-6 •ROSUVAS
•DEXELEX •ROSUVAS-EZ
•DIPROBEC •SEBIFIN TAB
•DIPROBEC-S •SELZIC-OD
•DIPROVATE PLUS •SIMOVOTIN
•DIPROVATE-G PLUS •SIMVOTIN TAB
•DIPROVATE-N PLUS •SOLITEN
•DIPROVATE-S PLUS •SOLZAM
•EARLIE ICON II •SOTRET
•ELIGARD •SPECTACEF
•ENHANCIN DPS •SPEELAC
•EPTIDE •SPORIDEX REDIMIX
•ESSVITAL •STANCEF
•ETROBAX •STANLIP
•EXOREX •SUDHINOL
•FEBOXA •SUDOPEN
•FENAK •SYMBIVA
•FLOTRAL •SYNASMA
•FORACET •TAZOBACT
•FORTIRON •TECZINE INSTAB
•FORZEST •TECZINE-AM
•FULACTIVE •TEVRAN
•GENTALENE PLUS •TICOVAN
•GRAMONEG-M •TOBITIL
•GRAMONEG-TN •TOZABACT
•HALOX •TRAMBAX
•HALOX LOTION •TREXYDIN
•HALOX-S •VEBALONE
•IMOGAM RABIES •VOLIX
•INVOZIDE •VORZU
•KEFLEX •XPHIL-NU
•KEFLOR-MR •ZANOCIN-OZ
•LEVANT •ZIVATOR
•LUCI •ZYGON


People Searching On This Page:

  • renvexy wiki
  • etrobax 90 in gwalior
  • норазол таблетка..
  • Renvexy forwin
  • Imipenem and Cilastatin impurity
  • ranbaxy range of products
  • RICONIA ranbaxy
  • packing of remicron mr available in Malaysia
  • mail id of hr of ranbaxy dewas
  • niftran syrup ranbaxy
  • the unique competencies of ranbaxy laboratories
  • ranbaxy philippines
  • manufacturer/supplier of arterolane maleate
  • SPACE matrix for ranbaxy
  • LULIFIN LOTION


Post Comments via Facebook Login

Mudassir
29-May-2012 11:02:50 IST
Kindly send me contact no. for job in ranbaxy.
nilesh raosaheb khule
10-Sep-2012 20:27:27 IST
Formulation Development and Evaluation of Once A Day Regioselective Dual Component Gastro Retentive Tablet of Rosuvastatin Calcium and Metoprolol Succinate.
 Post Your Comments without Login
Name : (required)

Email : (required)

Website :

Comment : (required)


Special Comment Tags:
New Line :           <br>
Bold Text :           <b>This is bold</b>
Underline Text :    <u>This is underlined</u>

30  + 7   =    

 Related Pages

Ranbaxy facing another Facility Problem?

News | Pharma Companies    Date: 25-Jul-2013  Views: 533
Another facility operated by Ranbaxy Laboratories in India is reported to have failed an inspection by the FDA, potentially adding to its regulatory compliance issues.A report in India's Business Standard newspaper suggests that Ranbaxy has been issued with a Form 483 notice by the FDA in the wake of an inspection at its plant in Mohali, one of its main production locations in India.

Environment, Health & Safety (EHS) Policy -Ranbaxy

Jobs | EHS    Date: 13-Nov-2012  Views: 1316
Care for the Environment is a core corporate value and as a part of this commitment, the company enunciated its Environment, Health & Safety (EHS) policy in 1993. The company’s EHS policy provides for the creation of a safe and healthy workplace and a clean environment for employees and the community. It aims at higher international standards in plant design, equipment selection, maintenance and operations. The policy seeks to manufacture products safely and in an environmentally responsible manner.

Production Officers - Ranbaxy Laboratories Limited

Jobs | Production | Punjab    Date: 12-May-2012  Views: 3751
Ranbaxy Laboratories LimitedIndia's largest drug maker and a leading MNC In pharmaceuticals Ranbaxy Laboratories Limited is looking for versatile. agile and learned professionals for the following positions for its formulations manufacturing plant based out of Mohali,Punjab

Quality Control/Quality Assurance Officers - Ranbaxy

Jobs    Date: 17-Apr-2012  Views: 16317
Ranbaxy Laboratories LimitedIndia's largest drug maker and a leading MNC In pharmaceuticals Ranbaxy Laboratories Limited is looking for versatile. agile and learned professionals for the following positions for its formulations manufacturing plant based out of Mohali,Punjab

Officer/Sr Officer/ Executive - QC - Ranbaxy Companies

Jobs | Quality Control    Date: 21-Nov-2011  Views: 6452
Job detail for the post of Officer/Sr Officer/ Executive - QC / Analytical Chemist in Ranbaxy Group Companies Baddi, 2 to 5 years of experience. Apply for the job Now ! Search Jobs in India by Functional Area, Industry and Location. Search Jobs in India - Delhi, Mumbai, Bangalore, Kolkata. Find career openings in top companies. Post your resume and find your dream job Now !.
X
Environment, Health & Safety (EHS) Policy  -Ranbaxy

Environment, Health & Safety (EHS) Policy -Ranbaxy

Date: 13-Nov-2012  Views: 1316

Ranbaxy Laboratories Limited,Job QA,QC,Production,R&D,F&D,Regulatory in Ranbaxy Company


Email Subscription



Searched Keywords
Renvexy Wiki | Etrobax 90 In Gwalior | Норазол Таблетка.. | Renvexy Forwin | Imipenem And Cilastatin Impurity | Ranbaxy Range Of Products | RICONIA Ranbaxy | Ranbaxy Philippines | Manufacturer/Supplier Of Arterolane Maleate | SPACE Matrix For Ranbaxy | LULIFIN LOTION | What Is Globalisation In Regard To International Business (Ranbaxy Pharmaceuticals | Which Pharmaceutical Company Manufacturing Garlic Pearls Manufacturing Cost | Ranbaxy US Research And Development | Portfolio.In.Ua Loc:IN | Euro-Trans.Com.Ua Loc:IN | Pillars.Co.Uk Loc:IN | Llevant.Com Loc:IN | Rambaxy Laboratories Custom Sinthesys | RANBAXY Limited | Email Macrogen.Com Loc:IN |

Search Engine's Visits
Google : 564 times | Yahoo : 1 times | Bing : 244 times |

Terms of Use